Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moody's Corporation (MCO) vs Smith & Nephew plc (SNN) Price & Performance

Moody's CorporationTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Moody's Corporation vs Smith & Nephew plc — how do they compare? Moody's Corporation trades at $493 (market cap $88.28B), while Smith & Nephew plc trades at $30.98 (market cap $12.64B). The key difference: Moody's Corporation is far larger — about 7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.

MCOSNN
Market Cap
$88.28B$12.64B
Sector
FinancialsHealth
52-Week High
$539.61$38.70
52-Week Low
$412.23$28.73
Enterprise Value
$94.08B$15.41B
Dividend Yield
0.82%2.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moody's Corporation

MCO trades at $505.12, down 1.12% today, with a bullish technical signal from moving averages but overbought RSI readings near 76. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $4.33, revenue growth to $7.72B in 2025, and robust profitability margins including a 31.69% net income margin. Recent news highlights AI integration initiatives and dividend sustainability, with a $1.03 dividend paid in June 2026.

Outlook remains positive given analyst consensus of $551.17 price target and 56% buy ratings, though valuation multiples like P/E of 36.65 pose risks if growth slows. Key risks include high debt levels and market sensitivity to credit cycles, but institutional support and recurring revenue model provide stability for long-term investors.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.

SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN